Meta-Analysis of Oral Anticoagulants and Adverse Outcomes in Atrial Fibrillation Patients After Intracranial Hemorrhage

Xin Liu, Siyu Guo, Zhicheng XuFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This meta-analysis investigates the effectiveness and safety of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) who have previously experienced an intracranial hemorrhage (ICH). The study found that OACs, particularly non-vitamin K antagonist oral anticoagulants (NOACs), can reduce the risk of stroke and death while maintaining a comparable risk of recurrent ICH and major bleeding compared to no OAC therapy.

What Problem Does This Paper Address?

Atrial fibrillation (AF) is a significant risk factor for stroke, and oral anticoagulants (OACs) are the standard treatment to prevent these events. However, a major concern with OACs is their association with intracranial hemorrhage (ICH), a potentially fatal complication. Consequently, patients who have already experienced an ICH are often excluded from clinical trials investigating OACs for stroke prevention in AF. This exclusion creates a knowledge gap regarding the net clinical benefit (efficacy and safety) of OAC therapy in this specific, high-risk patient population. The paper aims to address this by systematically analyzing existing studies to determine if the benefits of OACs in preventing further strokes outweigh the risks of bleeding or recurrent ICH in AF patients with a history of ICH.

Methods

The researchers conducted a meta-analysis, a statistical technique that combines the results of multiple independent studies to derive a more robust conclusion. They systematically searched two major databases, PubMed and Embase, for relevant randomized controlled trials (RCTs) and observational studies published up to March 2022. The search focused on studies comparing OAC therapy (including vitamin K antagonists - VKAs, and non-vitamin K antagonist oral anticoagulants - NOACs) against no OAC therapy, or comparing NOACs directly against VKAs, in patients with AF and a history of ICH.

Effectiveness outcomes included stroke or systemic embolism, ischemic stroke, and all-cause death. Safety outcomes focused on major bleeding and recurrent ICH. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were extracted from each study and pooled using a random-effects model, which accounts for potential heterogeneity between studies.

Datasets

The study did not introduce new datasets or benchmarks. Instead, it synthesized data from 14 previously published studies (2 RCTs and 12 observational cohorts) that met their inclusion criteria.

Key Insights and Ideas

  • Balancing Risks and Benefits: The core challenge is to balance the well-established stroke-prevention benefits of OACs against the increased risk of bleeding, especially ICH, in patients with a prior history of this event.
  • NOACs Emerge as Promising: The findings suggest that NOACs may offer a better risk-benefit profile than VKAs in this population, potentially due to their more predictable pharmacokinetics and lower risk of ICH compared to VKAs in general.
  • Heterogeneity is a Factor: The study acknowledges significant heterogeneity in some outcomes (e.g., all-cause death, recurrent ICH), indicating that the results should be interpreted with caution, and further research is needed to understand these variations.
  • The "No OAC" Group is Not Risk-Free: The study highlights that even without OACs, AF patients with a history of ICH are at risk for stroke, making the decision to resume anticoagulation a critical one.

Key Results

The meta-analysis yielded the following key findings:

  • OACs vs. No OACs:
    • OAC therapy was associated with a reduced risk of stroke or systemic embolism (HR = 0.65, 95% CI 0.53–0.81).
  • A reduced risk of ischemic stroke was also observed (HR = 0.70, 95% CI 0.60–0.82).
  • There was a significant reduction in all-cause death (HR = 0.43, 95% CI 0.27–0.70).
  • However, OAC therapy showed an upward trend in major bleeding (HR = 1.50, 95% CI 0.94–2.40).
  • No significant difference was found in the risk of recurrent ICH (HR = 0.91, 95% CI 0.53–1.55).
  • NOACs vs. VKAs:
    • NOAC therapy was associated with a reduced risk of stroke or systemic embolism compared to VKA therapy (HR = 0.83, 95% CI 0.70–0.98).
  • A reduced risk of all-cause death was observed with NOACs (HR = 0.67, 95% CI 0.53–0.84).
  • NOACs also showed a reduced risk of recurrent ICH compared to VKAs (HR = 0.68, 95% CI 0.54–0.86).
  • There was no significant difference in major bleeding between NOACs and VKAs (HR = 0.54, 95% CI 0.26–1.10).

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited RCT Data: The meta-analysis relied heavily on observational studies, with only two recent RCTs included. This limits the strength of the evidence, particularly for definitive conclusions.
  • Heterogeneity: Significant heterogeneity was observed in some outcomes, suggesting variations in study populations, ICH severity, imaging, and bleeding definitions that could influence results.
  • Subgroup Analysis Limitations: Due to limited data, the study could not perform subgroup analyses for different types of ICH (traumatic, spontaneous, OAC-related) or for specific NOAC agents (dabigatran, apixaban, rivaroxaban, edoxaban).
  • Timing of Anticoagulation: The varied timing of OAC initiation across studies prevented an analysis of early versus late anticoagulation strategies.
  • Hemorrhage Volume: The volume of hemorrhage, a crucial factor in anticoagulation decisions, could not be analyzed.

The authors suggest that further research, particularly well-designed RCTs with larger sample sizes and longer follow-up periods, is warranted to confirm these findings, explore specific NOAC subgroups, and investigate optimal anticoagulation strategies in this complex patient population. They also mention ongoing trials investigating left atrial appendage occlusion as an alternative for patients contraindicated to anticoagulation.

Summary updated

Abstract

The OAC therapy (especially VKA) revealed superior effectiveness in patients with AF after ICH, and the superiority of NOAC was also found, but some related evidence was limited.
BibTeX
@inproceedings{liu2022meta,
  author = {Xin Liu and Siyu Guo and Zhicheng Xu},
  title = {{Meta-Analysis of Oral Anticoagulants and Adverse Outcomes in Atrial Fibrillation Patients After Intracranial Hemorrhage}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.961000},
}
Figure